Risk assessment in deferred and recovered donors.
Risk assessment in deferred and recovered donors.
复制标题
DOI：
10.1007/s10561-021-09909-9
复制
发表时间：
2021-12
影响因子：
1.5
通讯作者：
Cavanaugh D
中科院分区：
文献类型：
--
作者：
Heck E;Corder V;Urban J;Petroll M;Timmons W;Cavanaugh D
血清学检测和供体风险评估访谈 (DRAI) 相结合，使组织移植成为治疗各种创伤和疾病的常见且安全的方式。 Donate Life America 报告称，有 30,000 名组织捐赠者每年提供超过 1,750,000 例组织移植。这项针对 188 例潜在捐赠者病例的研究解决了大都市区体检人员群体的风险评估问题，其中将延迟潜在捐赠者的血清学检测与 DRAI 筛查进行比较，从而确定是否适合组织采购。在评估筛查过程中通常无法对延迟病例进行此类血清学检测。这种比较可以深入了解 DRAI 筛查在推迟潜在血清学反应性供体方面的有效性。结果显示，在 65 个病例中，DRAI 筛查如何消除了大多数（但不是全部）恢复后发现的血清学反应性供体。结果强调需要将 DRAI 筛查和测试结合起来，以确保移植安全。
Serologic testing and Donor Risk Assessment Interview (DRAI) combined have made tissue transplantation a frequent and safe modality for a variety of trauma and disease conditions. Donate Life America reports 30,000 tissue donors providing more than 1,750,000 tissue transplants annually. This study of 188 potential donor cases addresses issues of risk assessment in a medical examiner population in a metropolitan area, where serologic testing of deferred potential donors were compared with the DRAI screening, which determined the suitability or non-suitability for tissue procurement. Such serologic testing of deferred cases is not usually available in evaluating screening processes. This comparison gives insight into the effectiveness of the DRAI screening in deferring potential serology reactive donors. Results show in 65 cases how the DRAI screening eliminates most, but not all of the serologically reactive donors identified post recovery. The result emphasizes the need for the combined process of DRAI screening and testing to assure transplantation safety.
影响因子：
3.1
作者：
Kaspar MB;Sterling RK
通讯作者：
Sterling RK